Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SRF617 with etrumadenant and zimberelimab in mCRPC
NCT05177770Phase 2Terminated
- Sponsor
- Coherus BioSciences, Inc.
- Start
- Jan 2022
- Primary completion
- Apr 2023
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of perenostobart in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Coherus BioSciences, Inc. Primary endpoints: Number of Participants With Response up to 168 days and Number of Participants With Adverse Events. Started Jan 2022; status: terminated.
02
Drugs
perenostobart
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT05177770.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05177770.